Pacira BioSciences, Inc. (PCRX)
USD 24.97
(1.67%)
USD 24.97
(1.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 87.67 Million USD | 45.48% |
| 2022 | 60.02 Million USD | -54.2% |
| 2021 | 131.06 Million USD | 182.77% |
| 2020 | 46.35 Million USD | 21.62% |
| 2019 | 38.11 Million USD | 139.46% |
| 2018 | 15.91 Million USD | 163.82% |
| 2017 | -24.93 Million USD | 22.13% |
| 2016 | -32.02 Million USD | -438.7% |
| 2015 | 9.45 Million USD | 283.06% |
| 2014 | -5.16 Million USD | 90.31% |
| 2013 | -53.28 Million USD | -8.1% |
| 2012 | -49.29 Million USD | -26.08% |
| 2011 | -39.1 Million USD | -74.78% |
| 2010 | -22.37 Million USD | 21.63% |
| 2009 | -28.54 Million USD | 37.07% |
| 2008 | -45.36 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 30.97 Million USD | 104.93% |
| 2024 Q1 | 15.11 Million USD | -55.5% |
| 2023 Q3 | 17.72 Million USD | -55.56% |
| 2023 Q4 | 33.96 Million USD | 91.67% |
| 2023 FY | 87.32 Million USD | 45.48% |
| 2023 Q2 | 39.87 Million USD | 228.26% |
| 2023 Q1 | 12.14 Million USD | -28.99% |
| 2022 Q4 | 17.1 Million USD | 48.62% |
| 2022 Q2 | 11.9 Million USD | -31.54% |
| 2022 Q1 | 17.39 Million USD | 312.94% |
| 2022 FY | 60.02 Million USD | -54.2% |
| 2022 Q3 | 11.51 Million USD | -3.33% |
| 2021 Q2 | 34.84 Million USD | 79.26% |
| 2021 Q1 | 19.43 Million USD | 3.48% |
| 2021 Q4 | 4.21 Million USD | -86.6% |
| 2021 Q3 | 31.43 Million USD | -9.79% |
| 2021 FY | 131.06 Million USD | 182.77% |
| 2020 Q1 | 17.09 Million USD | 898.48% |
| 2020 FY | 46.35 Million USD | 21.62% |
| 2020 Q2 | -7.14 Million USD | -141.81% |
| 2020 Q3 | 17.62 Million USD | 346.54% |
| 2020 Q4 | 18.78 Million USD | 6.6% |
| 2019 Q4 | 1.71 Million USD | -29.05% |
| 2019 Q2 | 5.27 Million USD | 388.88% |
| 2019 Q3 | 2.41 Million USD | -54.26% |
| 2019 FY | 38.11 Million USD | 139.46% |
| 2019 Q1 | 1.07 Million USD | -91.2% |
| 2018 Q3 | 4.04 Million USD | -38.11% |
| 2018 Q1 | -6.93 Million USD | -181.96% |
| 2018 FY | 15.91 Million USD | 163.82% |
| 2018 Q4 | 12.26 Million USD | 202.92% |
| 2018 Q2 | 6.54 Million USD | 194.29% |
| 2017 FY | -24.93 Million USD | 22.13% |
| 2017 Q4 | 8.46 Million USD | 336.95% |
| 2017 Q3 | -3.57 Million USD | 77.36% |
| 2017 Q2 | -15.78 Million USD | -12.31% |
| 2017 Q1 | -14.05 Million USD | -470.91% |
| 2016 Q4 | -2.46 Million USD | 88.21% |
| 2016 Q2 | -6.44 Million USD | -185.89% |
| 2016 Q1 | -2.25 Million USD | -177.24% |
| 2016 FY | -32.02 Million USD | -438.7% |
| 2016 Q3 | -20.86 Million USD | -223.79% |
| 2015 Q1 | 3.34 Million USD | -57.82% |
| 2015 Q4 | -813 Thousand USD | -115.91% |
| 2015 FY | 9.45 Million USD | 283.06% |
| 2015 Q3 | 5.1 Million USD | 181.02% |
| 2015 Q2 | 1.81 Million USD | -45.59% |
| 2014 Q4 | 7.92 Million USD | 904.06% |
| 2014 FY | -5.16 Million USD | 90.31% |
| 2014 Q3 | -985 Thousand USD | 65.34% |
| 2014 Q2 | -2.84 Million USD | 69.3% |
| 2014 Q1 | -9.25 Million USD | 5.71% |
| 2013 Q4 | -9.81 Million USD | 23.37% |
| 2013 Q1 | -18.64 Million USD | -17.79% |
| 2013 FY | -53.28 Million USD | -8.1% |
| 2013 Q2 | -12.01 Million USD | 35.59% |
| 2013 Q3 | -12.81 Million USD | -6.69% |
| 2012 Q2 | -6.62 Million USD | 40.5% |
| 2012 Q1 | -11.13 Million USD | 24.33% |
| 2012 Q3 | -15.7 Million USD | -137.04% |
| 2012 Q4 | -15.82 Million USD | -0.78% |
| 2012 FY | -49.29 Million USD | -26.08% |
| 2011 FY | -39.1 Million USD | -74.78% |
| 2011 Q1 | -7.12 Million USD | -25.39% |
| 2011 Q2 | -8.53 Million USD | -19.78% |
| 2011 Q3 | -8.73 Million USD | -2.37% |
| 2011 Q4 | -14.71 Million USD | -68.52% |
| 2010 Q4 | -5.68 Million USD | 11.95% |
| 2010 Q3 | -6.45 Million USD | -14.62% |
| 2010 Q2 | -5.62 Million USD | -21.95% |
| 2010 Q1 | -4.61 Million USD | 40.91% |
| 2010 FY | -22.37 Million USD | 21.63% |
| 2009 Q3 | -6.12 Million USD | 0.0% |
| 2009 Q4 | -7.81 Million USD | -27.61% |
| 2009 FY | -28.54 Million USD | 37.07% |
| 2008 FY | -45.36 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 47.488% |
| Embecta Corp. | 221.5 Million USD | 60.418% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -86.658% |
| Dynavax Technologies Corporation | -37.02 Million USD | 336.78% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 156.36% |
| PainReform Ltd. | -9.58 Million USD | 1014.806% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 680.552% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1932.174% |
| SCYNEXIS, Inc. | 72.66 Million USD | -20.65% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 3585.783% |
| Cosmos Health Inc. | -21.83 Million USD | 501.604% |
| Journey Medical Corporation | -2.07 Million USD | 4329.378% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1932.174% |
| Safety Shot Inc | -12.18 Million USD | 819.582% |
| Alpha Teknova, Inc. | -35.56 Million USD | 346.534% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 155.01% |
| Bright Green Corporation | -8.89 Million USD | 1086.067% |
| Procaps Group, S.A. | 38.97 Million USD | -124.963% |
| Theratechnologies Inc. | -10.62 Million USD | 925.021% |
| Harrow Health, Inc. | 580 Thousand USD | -15016.379% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1965.029% |
| Biofrontera Inc. | -22.67 Million USD | 486.625% |
| DURECT Corporation | -36.88 Million USD | 337.705% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 1763.978% |
| Cronos Group Inc. | -81.37 Million USD | 207.741% |
| OptiNose, Inc. | -22.74 Million USD | 485.418% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 58.057% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 323.929% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -594.071% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -600.0% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 2121.877% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 1511.65% |
| Radius Health, Inc. | -3.92 Million USD | 2333.758% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 2585.983% |
| ProPhase Labs, Inc. | -21.61 Million USD | 505.659% |
| Phibro Animal Health Corporation | 53.31 Million USD | -64.447% |
| Procaps Group S.A. | 52.32 Million USD | -67.562% |
| Alvotech | -354.86 Million USD | 124.707% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 1128.687% |
| Viatris Inc. | 766.2 Million USD | 88.557% |
| Rockwell Medical, Inc. | -6.67 Million USD | 1414.468% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 1768.729% |
| SIGA Technologies, Inc. | 83.62 Million USD | -4.848% |
| Tilray Brands, Inc. | -174.74 Million USD | 150.173% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -839.61% |
| Shineco, Inc. | -17.06 Million USD | 613.745% |
| PetIQ, Inc. | 60.01 Million USD | -46.088% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 1950.962% |
| Incannex Healthcare Limited | -30.04 Million USD | 391.851% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 65.056% |
| Alimera Sciences, Inc. | -1.47 Million USD | 6060.231% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1094.464% |
| Assertio Holdings, Inc. | -243.53 Million USD | 136.001% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 1587.939% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 743.847% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 662.235% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 537.281% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 163.602% |
| Hempacco Co., Inc. | -8.81 Million USD | 1094.918% |
| Talphera, Inc. | -16.88 Million USD | 619.125% |
| Alvotech | -354.86 Million USD | 124.707% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | -64.02% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 75.956% |
| Currenc Group, Inc. | -6.64 Million USD | 1419.257% |
| Kamada Ltd. | 10.06 Million USD | -771.174% |
| Indivior PLC | -4 Million USD | 2291.875% |
| Evoke Pharma, Inc. | -7.43 Million USD | 1279.872% |
| Flora Growth Corp. | -50.35 Million USD | 274.117% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 537.281% |
| Evolus, Inc. | -49.23 Million USD | 278.082% |
| HUTCHMED (China) Limited | 18.37 Million USD | -377.143% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 55.492% |
| Akanda Corp. | -10.05 Million USD | 972.269% |